To explore immune target-based therapeutics for HF, we used the CMAP platform to screen 15 small molecule compounds with the potential to reverse the high expression of hub genes, including telotristat, lomitapide, malotilate, tranylcypromine, TG-101348, cordycepin, tafamidis-meglumine, fostamatinib, delcorine, phenylbutazone, endo-IWR-1, scopolamine, anidulafungin, simvastatin and terconazole. The gene discussed is MANEA; the disease is hydrops fetalis.